無料プレビュー

Seagen Inc. (SGEN) · NASDAQ Global Select

プロフィール

Seagen Inc. is a biotechnology firm focused on the development and global commercialization of innovative cancer treatments. Its portfolio features several key oncology therapeutics, including ADCETRIS, an antibody-drug conjugate (ADC) utilized for Hodgkin lymphoma and CD30-positive T-cell lymphomas; PADCEV, another ADC designed to target Nectin-4 in patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor prescribed for adults battling advanced, inoperable, or metastatic HER2-positive breast cancer. Beyond its marketed drugs, Seagen

主要指標

株価: $228.74 (-0.07%)
時価総額: 432億ドル
PER（今期予想）: -58.5
PBR: 15.1
配当利回り: —
52週レンジ: $126.47 – $228.96
業種: Healthcare / Biotechnology
上場: NASDAQ Global Select
構成銘柄: —

比較会社: VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、VRNA Verona Pharma plc、COR Cencora, Inc.、ARGX argenx SE、BDX Becton, Dickinson and Company、RVMD Revolution Medicines, Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

更新: 2026-10-09